EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy

Ji Hyun Lee iD, Danbee Kang iD, Jin Seok Ahn iD, Eliseo Guallar iD, Juhee Cho iD, Ho Yun Lee iD

Journal of Cachexia, Sarcopenia and Muscle · 2023

DOI: 10.1002/jcsm.13367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2023. Verfasst von Ji Hyun Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Samsung Medical Center, Korea government (MSIT).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The obesity paradox in patients with advanced non‐small cell lung cancer receiving immune checkpoint inhibitor therapy has been observed, but its underlying mechanism is not fully understood. We aimed to investigate whether body composition affects the prognostic impact of obesity, as determined by body mass index (BMI), on survival.

Methods

This retrospective study evaluated the data collected from Asian patients who were treated with immune checkpoint inhibitors for advanced non‐small cell lung cancer between October 2015 and October 2021. We used abdominal cross‐sectional imaging to calculate the skeletal muscle and visceral fat indices (cm 2 /m 2 ) by dividing the cross‐sectional areas of the skeletal muscle and visceral fat by the height squared. Cox proportional‐hazards regression was performed to determine the correlation between BMI according to the Asia‐Pacific classification, body composition metrics and overall survival.

Results

We analysed the data of 820 patients (630 men and 190 women, with a mean age of 64.3 years [standard deviation: 10.4 years]) and observed 572 (69.8%) deaths with the 1‐year mortality rate of 0.58 (95% confidence interval, 0.55–0.62). Obese BMI was associated with longer overall survival, independent of clinical covariates (hazard ratio, 0.64; 95% confidence interval: 0.52–0.80). The prognostic value of obese BMI remained after additional adjustments for skeletal muscle index (hazard ratio, 0.68; 95% confidence interval, 0.53–0.87) or visceral fat index (hazard ratio, 0.54; 95% confidence interval: 0.41–0.70). No association was observed between sex and the impact of BMI on overall survival ( P ‐value for interaction >0.05).

Conclusions

In Asian patients with advanced non‐small cell lung cancer who received immune checkpoint inhibitors, obese BMI was associated with favourable overall survival independent of skeletal muscle or visceral fat mass.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsMaleHumansFemaleMiddle AgedImmune Checkpoint InhibitorsRetrospective StudiesObesity ParadoxObesity

Stichwörter der Autor:innen

Immune checkpoint inhibitorsImmunotherapyLung neoplasmsNon-small cell lung cancerTumour biomarkers

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Clinical Research Design and Evaluation, The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea.
  • Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Epidemiology and Medicine and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
  • Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
  • Department of Health Sciences and Technology, The Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea.

ORCID-Profile: Ji Hyun Lee, Danbee Kang, Jin Seok Ahn, Eliseo Guallar, Juhee Cho, Ho Yun Lee

Förderung

  • Samsung Medical Center
  • Korea government (MSIT)

Zitieren

APA

Lee, J. H., Kang, D., Ahn, J. S., Guallar, E., Cho, J., & Lee, H. Y. (2023). Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.13367

Vancouver

Lee JH, Kang D, Ahn JS, Guallar E, Cho J, Lee HY. Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy. Journal of Cachexia, Sarcopenia and Muscle. 2023. doi:10.1002/jcsm.13367

BibTeX
@article{Lee2023,
  author = {Lee, Ji Hyun and Kang, Danbee and Ahn, Jin Seok and Guallar, Eliseo and Cho, Juhee and Lee, Ho Yun},
  title = {Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2023},
  doi = {10.1002/jcsm.13367}
}
Kostenlos starten →